ライフサイエンスコーパス: tankyrase

1 nhibition of the telomere-associated protein tankyrase.

2 its binding partner, the scaffolding protein tankyrase.

3 ng with a poly(ADP-ribose) polymerase (PARP) tankyrase.

4 novel family of potent inhibitors for human tankyrases.

5 ies of potent flavone derivatives inhibiting tankyrases.

6 that AMPK activation by LKB1 is regulated by tankyrases.

7 nd human TRF1 that mediates their binding to tankyrases.

8 Here, we show that tankyrase 1 activity at telomeres is controlled by a ubi

9 Tankyrase 1 ADP-ribosylates TRF1 in vitro, and its overe

10 Tankyrase 1 ADP-ribosylates TRF1, inhibiting its binding

11 Tankyrase 1 and 2 are poly(ADP-ribose) polymerases that

12 Tankyrase 1 and 2 have been shown to be redundant, drugg

13 rticularly the poly-ADP-ribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt

14 nhibitor 16 displays high target affinity on tankyrase 1 and 2 with biochemical and cellular IC50 val

15 1 (hTRF1) and its interacting proteins TIN2, tankyrase 1 and 2, and PINX1 have been implicated in the

16 d we have found that striatin interacts with Tankyrase 1 and is subsequently poly-ADP-ribosylated.

17 TIN2 formed a ternary complex with TRF1 and tankyrase 1 and stabilized their interaction, an effect

18 nctions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2), regulators of the

19 Human TRF1 interacts with tankyrase 1 and tankyrase 2 proteins, two related member

20 inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2.

21 Overexpression of tankyrase 1 antagonizes both Mcl-1L-mediated cell surviv

22 We therefore sought to establish the role of tankyrase 1 at telomeres and to determine if tankyrase 2

23 bosyl)ation by tankyrase 1 without affecting tankyrase 1 automodification.

24 PARP activity in vitro, dependent on the GMD tankyrase 1 binding motif.

25 e 1 is reduced upon entry into mitosis, when tankyrase 1 binds to its other partners TRF1 (at telomer

26 We propose that inhibition of Tankyrase 1 could be therapeutically exploited in BRCA-a

27 Thus, interaction of Mcl-1L and Mcl-1S with tankyrase 1 could serve as a unique mechanism to decreas

28 Although tankyrase 1 down-regulates Mcl-1 protein expression, no

29 mosomes, telomeres rendered dysfunctional by tankyrase 1 engage in chromatid fusions almost exclusive

30 TAB182 coimmunoprecipitates with tankyrase 1 from human cells and serves as an acceptor o

31 Our findings indicate that tankyrase 1 has the unique capacity to promote both asse

32 nkyrase 1 with GMD in the cytosol sequesters tankyrase 1 in an inactive stable form that can be tappe

33 at K63-linked ubiquitin chains accumulate on tankyrase 1 in late S/G2 to promote its stabilization, a

34 nd TIN2 or SA1 abrogates the requirement for tankyrase 1 in mitotic progression.

35 We show that GMD is complexed to tankyrase 1 in the cytosol throughout interphase, but it

36 Overexpression of tankyrase 1 in the nucleus promotes telomere elongation,

37 as an acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in vitro.

38 In yeast and mammalian cells, tankyrase 1 interacts with both Mcl-1L and Mcl-1S, but d

39 We show that endogenous tankyrase 1 is a component of the human telomeric comple

40 Tankyrase 1 is a poly(ADP-ribose) polymerase (PARP) that

41 that the selectivity caused by inhibition of Tankyrase 1 is associated with an exacerbation of the ce

42 oughout interphase, but its association with tankyrase 1 is reduced upon entry into mitosis, when tan

43 Human tankyrase 1 is reported to ADP-ribosylate TRF1 and to do

44 ta-catenin turnover pathway as inhibition of tankyrase 1 led to high AEC axin levels, loss of pY654-b

45 These findings suggest that tankyrase 1 may act as a scaffold for large molecular ma

46 Analysis of truncated tankyrase 1 mutants indicated that the first 10 ankyrin

47 We show that either tankyrase 1 or 2 is sufficient to maintain telomere leng

48 Indeed, we show that GMD inhibits tankyrase 1 PARP activity in vitro, dependent on the GMD

49 However, it is not known how tankyrase 1 PARP activity is regulated.

50 We have shown that tankyrase 1 polymerizes through its sterile alpha motif

51 Tankyrase 1 recognizes a linear six-amino-acid degenerat

52 romotes telomere elongation, suggesting that tankyrase 1 regulates access of telomerase to the telome

53 ults showed that ADP-ribosylation of TRF1 by tankyrase 1 released TRF1 from telomeres and promoted te

54 We demonstrate that telomere elongation by tankyrase 1 requires the catalytic activity of the PARP

55 In addition to its telomeric localization, tankyrase 1 resides at multiple subcellular sites, sugge

56 ficient TRF1 and as a consequence inadequate tankyrase 1 to resolve sister telomere cohesion.

57 Binding of partner proteins to tankyrase 1 usually results in their poly(ADP-ribosyl)at

58 st potent hit compound (X066/Y469) inhibited tankyrase 1 with an IC50 value of 250 nM.

59 We speculate that association of tankyrase 1 with GMD in the cytosol sequesters tankyrase

60 Furthermore, coexpression of tankyrase 1 with Mcl-1L or Mcl-1S decreased the levels o

61 rotected TRF1 from poly(ADP-ribosyl)ation by tankyrase 1 without affecting tankyrase 1 automodificati

62 roteins, TRF1 (an acceptor of PARsylation by tankyrase 1) and TIN2 (a TRF1 binding partner) each bind

63 Tankyrase 1, a human telomeric poly(ADP-ribose) polymera

64 Tankyrase 1, a human telomeric poly(ADP-ribose) polymera

65 at telomeres can be induced by inhibition of tankyrase 1, a poly(ADP-ribose) polymerase that is requi

66 itors of the potential pharmaceutical target tankyrase 1, a poly(ADP-ribose) polymerase.

67 Knockdown of tankyrase 1, a telomeric poly(ADP-ribose) polymerase cau

68 In cells depleted for tankyrase 1, a telomeric poly(ADP-ribose) polymerase, si

69 proposed to have activity similar to that of tankyrase 1, although tankyrase 2 function has been less

70 the enzymes that catalyze it (PARP1, PARP2, tankyrase 1, and tankyrase 2) function to maintain genom

71 target of the poly (ADP-ribose) polymerases Tankyrase 1, and we have found that striatin interacts w

72 res requires the poly(ADP-ribose) polymerase tankyrase 1, but the mechanism that times its action is

73 ankyrase 2, like its closely related homolog tankyrase 1, can function as a positive regulator of tel

74 e after the bulk of the genome, dependent on tankyrase 1, condensin II, and topoisomerase IIalpha.

75 vivo, depletion of GMD led to degradation of tankyrase 1, dependent on the catalytic PARP activity of

76 hibition of the telomere-associated protein, Tankyrase 1, is also selectively lethal with BRCA defici

77 und, 22 (MN-64), showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling in

78 1.1 binds to the poly(ADP-ribose) polymerase tankyrase 1, preventing it from localizing to telomeres

79 oly(adenosine diphosphate ribose) polymerase tankyrase 1, sister telomere resolution is blocked.

80 entification of a closely related homolog of tankyrase 1, tankyrase 2, opens the possibility for a se

81 on of the positive telomere length regulator tankyrase 1, the TIN2/TINT1 complex remained on telomere

82 ng protein TRF1 and its interacting partners tankyrase 1, TIN2 and PINX1.

83 e (PARP) activity of its interacting partner tankyrase 1, which abolishes its DNA binding activity in

84 F8 conjugates K63-linked ubiquitin chains to tankyrase 1, while in G1 phase such ubiquitin chains are

85 Here we identify TAB182, a novel tankyrase 1-binding protein of 182 kDa.

86 Thus, telomeres may require a unique tankyrase 1-dependent mechanism for sister chromatid res

87 resolution of sister telomeres in mitosis in tankyrase 1-depleted cells.

88 e telomeric repeat binding factor 1, another tankyrase 1-interacting protein.

89 We discuss potential roles for tankyrase 1-mediated higher order complexes at telomeres

90 hat can also be rescued by overexpression of tankyrase 1.

91 se delay can be rescued by overexpression of tankyrase 1.

92 r binding partners, GMD is not PARsylated by tankyrase 1.

93 dependent on the catalytic PARP activity of tankyrase 1.

94 ,6-dehydratase (GMD) as a binding partner of tankyrase 1.

95 n cells overexpressing a PARP-dead mutant of tankyrase 1.

96 t also observed with the PARP-dead mutant of tankyrase 1.

97 in domain (comprising 24 ankyrin repeats) of tankyrase 1.

98 wo-hybrid screening and found cDNAs encoding tankyrase 1.

99 25 amino acids is sufficient for binding to tankyrase 1.

100 ve well conserved ankyrin repeat clusters in tankyrase 1.

101 Tankyrases 1 and 2 (TNKS1/2) are promising pharmacologic

102 Tankyrases 1 and 2 (TNKS1/2) are promising pharmacologic

103 Tankyrases 1 and 2 are central biotargets in the WNT/bet

104 Tankyrases 1 and 2 are members of the poly(ADP-ribose) p

105 This finding suggests that either mouse tankyrases 1 and 2 have redundant functions in telomere

106 07-LK (66) displayed high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM

107 Human tankyrase-1 (TNKS) is a member of the poly(ADP-ribose) p

108 Tankyrase-1 and -2 are closely related poly(ADP-ribose)

109 cks this motif and thus does not bind either tankyrase-1 or -2.

110 Using this method, PARP-1 and tankyrase-1 substrate proteins were labeled by a fluores

111 Several PARPs, such as PARP-1 and Tankyrase-1, are known to play important roles in DNA re

112 Poly(ADP-ribose) (pADPr), made by PARP-5a/tankyrase-1, localizes to the poles of mitotic spindles

113 haracterization of a second human tankyrase, tankyrase 2 (TANK2), which can also interact with TRF1 b

114 bition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2), regulators of the beta-catenin de

115 Tankyrase 2 (Tnks2) is a poly(ADP-ribose) polymerase (PA

116 These findings establish tankyrase 2 as a bona fide PARP, with itself and TRF1 as

117 To investigate a potential role for tankyrase 2 at telomeres, recombinant tankyrase 2 was su

118 n, and suggest the possibility of a role for tankyrase 2 at telomeres.

119 have assessed the in vivo function of mouse tankyrase 2 by germ line gene inactivation and show that

120 We report here crystal structures of human tankyrase 2 catalytic fragment in complex with a byprodu

121 Tankyrase 2 deficiency did result in a significant decre

122 in telomere length maintenance or that mouse tankyrase 2 differs from human tankyrase 2 in its role i

123 e inactivation and show that inactivation of tankyrase 2 does not result in detectable alteration in

124 ity similar to that of tankyrase 1, although tankyrase 2 function has been less extensively character

125 e, most marked in male mice, suggesting that tankyrase 2 functions in potentially telomerase-independ

126 or that mouse tankyrase 2 differs from human tankyrase 2 in its role in telomere length maintenance.

127 Binding of these inhibitors to tankyrase 2 induces specific conformational changes.

128 oids, we performed a systematic screening of tankyrase 2 inhibitory activity using 500 natural and na

129 Human tankyrase 2 is proposed to have activity similar to that

130 tankyrase 1 at telomeres and to determine if tankyrase 2 might have a telomeric function.

131 Tankyrase 2 poly(ADP-ribosyl)ated itself and TRF1.

132 Human TRF1 interacts with tankyrase 1 and tankyrase 2 proteins, two related members of the tankyra

133 le for tankyrase 2 at telomeres, recombinant tankyrase 2 was subjected to an in vitro PARP assay.

134 catalyze it (PARP1, PARP2, tankyrase 1, and tankyrase 2) function to maintain genome stability throu

135 We show here by overexpression studies that tankyrase 2, like its closely related homolog tankyrase

136 of a closely related homolog of tankyrase 1, tankyrase 2, opens the possibility for a second PARP at

137 n complex with the catalytic domain of human tankyrase 2.

138 res bind to the nicotinamide binding site of tankyrase 2.

139 oly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2.

140 Here, we show that tankyrase, a poly(ADP-ribosyl) polymerase that regulates

141 939, which targets the enzymatic activity of tankyrase, acted to stabilize Axin2 levels in OLPs from

142 udy reveals a redox mechanism for regulating tankyrase activity and implicates PrxII as a targetable

143 rnative therapeutic approaches to inhibiting tankyrase activity in cancer and other conditions.

144 Suppression of tankyrase activity using knockdown or chemical inhibitio

145 tam-based nicotinamide mimetics that inhibit tankyrase activity, such as XAV939, are well-known, here

146 ion of Iduna causes the accumulation of both Tankyrase and Axin.

147 s disrupt the interaction between SH3BP2 and Tankyrase and describe rules for substrate recognition b

148 ay-based pooled CRISPR screen and identified tankyrase and its associated E3 ligase RNF146 as positiv

149 n contributes to the known colocalization of tankyrase and NuMA at mitotic spindle poles.

150 al cancers with APC mutation, PrxII binds to tankyrase and prevents its oxidative inactivation, there

151 Taken together, these findings suggest that tankyrase and RNF146 are major up-stream regulators of L

152 rified NuMA as an RXXPDG-mediated partner of tankyrase and suggest that this interaction contributes

153 indings therefore reveal a critical role for tankyrase and the canonical Wnt pathway in maintaining l

154 Inhibition of tankyrase and various other components of the Wnt pathwa

155 deficiency could promote the degradation of tankyrases and consequent stabilization of Axin to antag

156 here structural differences are seen between tankyrases and other poly(ADP-ribose) polymerase (PARP)

157 lar mechanism that regulates the turnover of tankyrases and the possibility of targeting the stabilit

158 Flavones have been shown to inhibit tankyrases and we report here the discovery of more pote

159 enable probing the scaffolding functions of tankyrase, and may, in the future, provide potential alt

160 Thus, tankyrases appear to be master scaffolding proteins that

161 a fragment-based screening programme against tankyrase ARC domains, using a combination of biophysica

162 Direct binding of PrxII to tankyrase ARC4/5 domains seems to be crucial for protect

163 Tankyrases are ADP-ribosyltransferases that play key rol

164 Tankyrases are novel poly(ADP-ribose) polymerases that h

165 Tankyrases are poly(ADP-ribose) polymerases that have ma

166 We show that tankyrases are required for Notch2 to exit the plasma me

167 Using the ankyrin domain of tankyrase as a bait in a yeast two-hybrid screen, we als

168 is implies a common scaffolding function for tankyrases at each location, with specific tankyrase int

169 cell growth, indicating the ATRX-macroH2A1.1-tankyrase axis as a potential therapeutic target in ALT

170 Targeting the Wnt-tankyrase-beta-catenin pathway together with EGFR inhibi

171 Mutation of the tankyrase-binding motif (TBM) on TRF1 (13R/18G to AA) di

172 The ARCs recognise a conserved tankyrase-binding peptide motif (TBM).

173 ponsive aminopeptidase), and TAB182 (182-kDa tankyrase-binding protein).

174 The mechanism by which tankyrase binds to diverse proteins has not been investi

175 he possibility of targeting the stability of tankyrases by antagonizing their interaction with USP25

176 inantly to the adenosine binding site of the tankyrase catalytic domain.

177 Tankyrases constitute potential drug targets for cancer

178 ssed tankyrase leading to formation of large tankyrase-containing vesicles, disruption of Golgi struc

179 cal models on how other proteins as TIN2 and tankyrase contribute to regulate TRF1 function.

180 Quantitative analysis of the proteome of tankyrase double knockout cells using isobaric tandem ma

181 mall molecules that modulate the activity of Tankyrase enzymes and glycogen synthase kinase 3 beta (G

182 Inhibition of the PARP superfamily tankyrase enzymes suppresses Wnt/beta-catenin signalling

183 yrase 2 proteins, two related members of the tankyrase family shown to have poly(ADP-ribose) polymera

184 5 domains seems to be crucial for protecting tankyrase from oxidative inactivation.

185 nts to novel potential strategies to inhibit Tankyrase function in oncogenic Wnt signaling.

186 ndent "scaffolding" mechanisms contribute to tankyrase function.

187 In addition to binding IRAP, Tankyrase has also been shown to bind the deubiquinating

188 Potent and selective inhibitors of tankyrases have recently been characterized to bind to a

189 along the length of the telomere (TRF1/TIN2/tankyrase in humans and Rap1/Rif1/Rif2 in budding yeast)

190 egulation of PTEN and highlighted a role for tankyrases in the PTEN-AKT pathway that can be explored

191 the PARP-dependent Axin1 degradation through tankyrase inactivation.

192 ike naive states with only WNT, MEK/ERK, and tankyrase inhibition (LIF-3i).

193 Our data suggest that tankyrase inhibition could serve as a novel strategy to

194 r the level of AXIN protein stabilization by tankyrase inhibition is sufficient to impact tumor growt

195 Tankyrase inhibition promoted a stable acquisition of a

196 an undifferentiated state may be blocked by tankyrase inhibition.

197 Mice given a tankyrase inhibitor (50 mg/kg orally) daily for 7 days b

198 XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in v

199 Similarly, the tankyrase inhibitor G007-LK effectively regulates liver

200 elationship study was conducted based on the tankyrase inhibitor JW74 (1).

201 entification of a novel potent and selective tankyrase inhibitor that binds to both the nicotinamide

202 ipophilic efficiency, NVP-TNKS656 is a novel tankyrase inhibitor that is well suited for further in v

203 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinet

204 resulted in compound 5k, a potent, selective tankyrase inhibitor with favorable pharmacokinetic prope

205 th old mice were treated with Nefopam or the tankyrase inhibitor XAV939 after a tibia fracture.

206 The CR mutant escV or the tankyrase inhibitor XAV939 attenuated these responses.

207 Flavone has been previously identified as a tankyrase inhibitor, and to further elucidate whether ta

208 Tankyrase inhibitor, but not porcupine inhibitor, which

209 In the xenograft model most sensitive to tankyrase inhibitor, COLO-320DM, G007-LK inhibits cell-c

210 nct small-molecule Wnt pathway inhibitors (a tankyrase inhibitor, XAV-939, and the U.S. Food and Drug

211 This tankyrase inhibitor-CDK4/6 inhibitor combinatorial effec

212 Tankyrase inhibitor-induced stabilization of angiomotins

213 be significantly improved by reversion to a tankyrase inhibitor-regulated human naive epiblast-like

214 More broadly, tankyrase inhibitor-regulated naive hiPSC (N-hiPSC) repr

215 uinoxaline 41, a highly potent and selective tankyrase inhibitor.

216 Interest is mounting in tankyrase inhibitors (TNKSi), which destabilize beta-cat

217 identification of more potent and selective tankyrase inhibitors 22 and 49 with improved pharmacokin

218 asis for rational development of flavones as tankyrase inhibitors and guides the development of other

219 nostic and safety concerns to be overcome as tankyrase inhibitors are advanced into the clinic.

220 We have previously developed tankyrase inhibitors bearing a 1,2,4-triazole moiety and

221 We show that novel tankyrase inhibitors completely block ligand-driven Wnt/

222 lish proof-of-concept antitumor efficacy for tankyrase inhibitors in APC-mutant CRC models and uncove

223 d cell lines, demonstrating the potential of tankyrase inhibitors in oncology.

224 LKB1 activation by tankyrase inhibitors induces AMPK activation and suppres

225 h signaling is commonly activated in cancer, tankyrase inhibitors may have therapeutic potential in t

226 All currently available tankyrase inhibitors target the catalytic domain and inh

227 33 and resulted in highly potent, selective tankyrase inhibitors that are novel three pocket binders

228 es were identified and optimized into potent tankyrase inhibitors through SAR exploration around the

229 All identified tankyrase inhibitors were flavones.

230 modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic prope

231 developed potent and specific small-molecule tankyrase inhibitors, G007-LK and G244-LM, that reduce W

232 uggests clues for the further development of tankyrase inhibitors.

233 ted with other CDK4/6 inhibitors and toolbox tankyrase inhibitors.

234 e-guided lead optimization approach of these tankyrase inhibitors.

235 tures gave instant access to a new series of tankyrase inhibitors.

236 Here we demonstrate that USP25 and Tankyrase interact, and colocalise with GLUT4 in insulin

237 Tankyrases interact with and ribosylate LKB1, promoting

238 We showed that tankyrases interact with and ribosylate PTEN, which prom

239 r tankyrases at each location, with specific tankyrase interaction partners conferring location-speci

240 ere we report that the inhibition of TRF1 by tankyrase is in turn controlled by a second TRF1-interac

241 us, regulation of the levels and activity of tankyrases is mechanistically important in controlling W

242 Both tankyrase isoforms interact with a highly conserved doma

243 cotinamide, and with selective inhibitors of tankyrases (IWR-1) and PARPs 1 and 2 (olaparib).

244 h SAM-dependent association of overexpressed tankyrase leading to formation of large tankyrase-contai

245 In patients with lung cancer, tankyrase levels negatively correlate with p-AMPK levels

246 Inhibition of tankyrases may offer a novel approach to the treatment o

247 Tankyrase-mediated PARylation marks protein targets for

248 timulated cells, Axin is rapidly modified by tankyrase-mediated poly(ADP-ribosyl)ation, which promote

249 lar poly(ADP-ribose) polymerases (PARPs) and tankyrases modulates chromatin structure, telomere elong

250 novel, drug-like small molecule inhibitor of tankyrase MSC2504877 that inhibits the growth of APC mut

251 Inhibition of tankyrase or depletion of RNF146 stabilizes angiomotins.

252 flavones show up to 200-fold selectivity for tankyrases over ARTD1.

253 also found the RXXPDG motif in six candidate tankyrase partners, including the nuclear/mitotic appara

254 Finally, tankyrase polymers are dissociated efficiently by poly(A

255 These features make tankyrases potential targets for treatment of cancer.

256 ic ablation or pharmacological inhibition of tankyrase prominently suppresses YAP activity and YAP ta

257 Our targets are the tankyrase proteins (TNKS), poly(ADP-ribose) polymerases

258 ripping TRF1 off the telomeres by expressing tankyrase reduced telomere recruitment of not only TIN2

259 such rules paves the way to identifying all Tankyrase-regulated pathways in cells.

260 the use of 41 to investigate the biology of tankyrase, revealing the compound induced growth inhibit

261 tors target the catalytic domain and inhibit tankyrase's poly(ADP-ribosyl)ation function.

262 o and in cells, whereas IWR1 and AZ-6102 are tankyrase selective.

263 cate that post-transcriptional regulation of tankyrase serves as a ligand-independent developmental m

264 ve as starting points for the development of tankyrase substrate binding antagonists.

265 gative regulators of YAP signaling, as novel tankyrase substrates.

266 Tankyrase (TANK1) is a human telomere-associated poly(AD

267 we report characterization of a second human tankyrase, tankyrase 2 (TANK2), which can also interact

268 nt of wild-type embryos with an inhibitor of Tankyrase that stabilizes Axin proteins also causes inhi

269 Angiomotins physically interact with tankyrase through a highly conserved motif at their N te

270 compound 8 was identified as an inhibitor of tankyrases through a combination of substructure searchi

271 The poly(ADP-ribose) polymerase (PARP) Tankyrase (TNKS and TNKS2) is paramount to Wnt-beta-cate

272 We identify the ADP-ribosyltransferase tankyrase (TNKS) and the 19S assembly chaperones dp27 an

273 he poly(ADP-ribose) polymerase (PARP) enzyme Tankyrase (TNKS) antagonizes destruction complex activit

274 Inhibitors of the ADP-ribose polymerase Tankyrase (Tnks) have become lead therapeutic candidates

275 sis coli (APC) and the ADP-ribose polymerase Tankyrase (Tnks) have evolutionarily conserved roles in

276 molecule inhibitors of the Wnt pathway, and tankyrase (TNKS) inhibition has been demonstrated to ant

277 Tankyrase (TNKS) is a Golgi-associated poly-ADP-ribose p

278 Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PAR

279 Tankyrase (TNKS) is a telomere-associated poly-ADP ribos

280 telomere protection enzymes belonging to the tankyrase (Tnks) subfamily of poly(ADP-ribose) polymeras

281 ed by its poly-ADP-ribosylation catalyzed by tankyrase (TNKS), which requires the direct interaction

282 Axin and find that the ADP-ribose polymerase Tankyrase (Tnks)--known to target Axin for proteolysis-r

283 6 directly interacts with the PAR polymerase tankyrase (TNKS).

284 The PARP enzyme and scaffolding protein tankyrase (TNKS, TNKS2) uses its ankyrin repeat clusters

285 Tankyrases (TNKS) play roles in Wnt signaling, telomere

286 The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of beta-ca

287 Tankyrases (TNKS1 and TNKS2) are proteins in the poly AD

288 Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8

289 tent and isoform selective toward inhibiting tankyrases (TNKSs) than the "standard" inhibitor 1 (XAV9

290 onstrate that polymerization is required for Tankyrase to drive beta-catenin-dependent transcription.

291 eric state supports PARP activity and allows Tankyrase to effectively access destruction complexes th

292 TRF1 binding allows tankyrase to regulate telomere dynamics in human cells,

293 ells, whereas IRAP binding presumably allows tankyrase to regulate the targeting of IRAP.

294 We found that USP25 directly interacted with tankyrases to promote their deubiquitination and stabili

295 Potencies of the active flavones toward tankyrases vary between 50 nM and 1.1 muM, and flavones

296 Tankyrase was expressed in 85% of the glioblastoma tissu

297 Furthermore, tankyrases were up-regulated and negatively correlated w

298 Tankyrase, which poly(ADP-ribosyl)ates and thereby desta

299 We identified PTEN as a novel substrate of tankyrases, which are members of the poly(ADP-ribose) po

300 inhibitor, and to further elucidate whether tankyrases would be inhibited by other flavonoids, we pe